Xeris Biopharma Holdings, Inc. (XERS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John P. Shannon | CEO & Director | 1.07M | -- | 1962 |
| Mr. Kevin McCulloch | President & COO | 777.05k | -- | 1964 |
| Mr. Steven M. Pieper | Chief Financial Officer | 747.02k | 30k | 1978 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 767.83k | -- | 1964 |
| Mr. Paul R. Edick J.D. | Senior Advisor | 2.6M | -- | 1956 |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | -- | -- | -- |
| Ms. Kendal Korte | Senior Vice President of Human Resources | -- | -- | -- |
| Dr. Anh Nguyen M.B.A., M.D. | Chief Medical Officer | -- | -- | 1975 |
Xeris Biopharma Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 394
Description
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Corporate Governance
Upcoming Events
August 6, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Xeris Biopharma Holdings, Inc. Earnings Date
Recent Events
August 6, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission